In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction.

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

particularly in the SURMOUNT-1 Phase 3 trial. In this study, tirzepatide has demonstrated significant weight loss results, with a maximum dose achieving weight loss percentages that are ...

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher doses expected in the coming months. Tirzepatide is administered ...

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.

and Zepbound (tirzepatide). However, in October, Eli Lilly reported slower-than-expected Q3 sales, with Mounjaro generating $3.11bn globally and Zepbound generating $1.26bn in the US, according to ...

Crucially, the top-line reduction differed very little from the weight loss seen with Eli Lilly's combined GIP/GLP-1 agonist Zepbound (tirzepatide) at 72 weeks in the SURMOUNT-1 study, which was a ...

5 de Lemos, J. A. et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index ≥27 kg/m(2): SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension ...